The most complete and definitive reference to all aspects of poultry diseases, Diseases of Poultry, Fourteenth Edition has been fully revised and updated to offer a comprehensive survey of current knowledge. Updates the definitive reference of poultry health and disease Provides more clinically relevant information on management of specific diseases, contributed by clinical poultry veterinarians Offers information on disease control in organic and antibiotic-free production Presents more concise, streamlined chapters for ease of use Incorporates advances in the field, from new diagnostic tools and information to changes brought about by the increasing globalization and the re-emergence of zoonotic pathogens

Updated and much expanded, the Second Edition of Parasitic Protozoa is designed to be useful to physicians, veterinarians, and research scientists concerned with diseases caused by protozoa in man, and in domestic and wild animals including fish, mollusks and insects, as well as the more commonly considered vertebrate animals. Each section contains information on disease pathogens, treatment, diagnosis, and epidemiology of the diseases caused by the various protozoans. The book is not limited to these medically-oriented subjects, but treats taxonomy, morphology, and metabolism of the organisms in such a way as to be of interest to scientists and graduate students working in the field of protozoology. The entire edition, published in ten volumes, is arranged so that subjects of common interest occupy individual volumes.

Everything you need to pass the NAPLEX® – comprehensive study material and two practice exams – in one student-reviewed package Written by an instructor who has taught thousand of students, this all-in-one study guide was developed and reviewed by pharmacists, faculty, students, and recent graduates – so you know it contains only the most relevant, up-to-date conent. You’ll find valuable foundational material and chapter-ending case application questions that cover every key topic included on the NAPLEX. Two downloadable practice tests with a total of 370 questions allowing you to pinpoint your weaknesses. Includes: Coverage that is organized around the NABP competencies and designed to sharpen problem-solving skills, put must-know information at your fingertips, and improve exam-taking ability More than 1400 case application questions, each with a detailed explanation of both correct and incorrect answer choices Takeaway Points at the end of every chapter that summarize key concepts Two complete downloadable practice tests, each with 185 questions

New emerging diseases, new diagnostic modalities for resource-poor settings, new vaccine schedules ... all significant, recent developments in the fast-changing field of tropical medicine. Hunter's Tropical Medicine and Emerging Infectious Diseases, 10th Edition, keeps you up to date with everything from infectious diseases and environmental issues through poisoning and toxicology, animal injuries, and nutritional and micronutrient deficiencies that result from traveling to tropical or subtropical regions. This comprehensive resource provides authoritative clinical guidance, useful statistics, and chapters covering organs, skills, and services, as well as traditional pathogen-based content. You'll get a full understanding of how to recognize and treat these unique health issues, no matter how widespread or difficult to control. - Includes important updates on malaria, leishmaniasis, tuberculosis and HIV, as well as coverage of Ebola, Zika virus, Chikungunya, and other emerging pathogens. - Provides new vaccine schedules and information on implementation. - Features five all-new chapters: Neglected Tropical Diseases: Public Health Control Programs and Mass Drug Administration; Health System and Health Care Delivery; Zika; Medical Entomology; and Vector Control – as well as 250 new images throughout. - Presents the common characteristics and methods of transmission for each tropical disease, as well as the applicable diagnosis, treatment, control, and disease prevention techniques. - Contains skills-based chapters such as dentistry, neonatal pediatrics and ICMI, and surgery in the tropics, and service-based chapters such as transfusion in resource-poor settings, microbiology, and imaging. - Discusses maladies such as delusional parasitosis that are often seen in returning travelers, including those making international adoptions, transplant patients, medical tourists, and more. - Enhanced eBook version included with purchase, which allows you to access all of the text, figures, and references from the book on a variety of devices.

Protozoan infections that are endemic in countries with limited economic resources pose a significant public health challenge to affected communities and some of these diseases are categorized as neglected tropical diseases by the World Health Organization. At the moment, there is an urgent need to identify and develop new antiprotozoal drugs. Antiprotozoal Drug Discovery: A Challenge That Remains brings together research from all scientists (including parasitologists, chemists, biologists among others) involved in the field of antiprotozoal experimental pharmacology, drug design and natural product research. The monograph is a compilation of review chapters written by experts on medical parasitology and pharmacology that covers a wide range of topics such as general characteristics of protozoan diseases (malaria, toxoplasmosis, Chagas’ disease, leishmaniasis, trichomoniasis) prophylaxis, treatments, natural products and rational drug design. The contents of this book are useful to medical microbiologists and pharmaceutical scientists seeking to update their knowledge about antiprotozoal drug design.

One of the top four contributors to the global burden of disease is diarrheal infections. Intestinal parasites are major causes of morbidity and mortality associated with diarrheal diseases in both the developed and developing world. Amebiasis is responsible for 50 million cases of invasive disease and 70,000 deaths annually in the world. Giardiasis has an estimated worldwide prevalence of 280 million cases annually. In developed countries, Giardia lamblia infects about 2% of adults and 6-8% of children. The prevalence of G. lamblia infection is generally higher in developing countries, ranging from 3% to 90%. Furthermore, giardial infections contribute substantially to the 2.5 million annual deaths from diarrheal disease. In Asia, Africa, and Latin America, about 500,000 new giardiasis cases are reported each year. Cryptosporidium accounts for 20% and 9% of diarrheal episodes in children in developing and developed countries, respectively. Infection with Cryptosporidium can be chronic and especially debilitating in immunosuppressed individuals and malnourished children. A recent study to measure disease burden, based on disability-adjusted life years (DALYs), found that cryptosporidiosis and amebiasis produce about 10.6 million DALYs. This exceeds the DALYs of any helminth infection currently being targeted by the World Health Organization for preventive chemotherapy. Because of its link with poverty, Giardia and Cryptosporidium were included in the WHO Neglected Diseases Initiative in 2004. E. histolytica, G. lamblia, and C. parvum have been listed by the National Institutes of Health (NIH) as category B priority biodefense pathogens due to low infectious dose and potential for dissemination through compromised food and water supplies in the United States. Despite the prevalence of amebiasis, giardiasis, and cryptosporidiosis there are no vaccines or prophylactic drugs. The first-line drugs for invasive amebiasis and giardiasis chemotherapy are nitroimidazoles, with the prototype, metronidazole, being the most common drug used worldwide. Metronidazole has been shown to be both mutagenic in a microbiological system and carcinogenic to rodents, and frequently causes gastrointestinal side effects. In spite of the efficacy of nitroimidazole drugs, treatment failures in giardiasis occur in up to 20% of cases. Clinical resistance of G. lamblia to metronidazole is proven and cross resistance is a concern with all commonly used antigiardial drugs. Nitazoxanide, the only FDA-approved drug for the treatment of cryptosporidiosis, is effective in the treatment of immunocompetent patients and partially effective for immunosuppressed patients. Therefore, it is critical to search for more effective drugs to treat amebiasis, giardiasis, and cryptosporidiosis. This Research Topic for Frontiers in Microbiology will explore the recent progress in drug development for parasitic diarrheal diseases. This includes an understanding of drug resistance mechanisms. We would also welcome submissions on the drug development for other diarrheal parasites. We hope that this research topic will include a comprehensive survey of various attempts by the parasitology research community to create effective drugs for these diseases.

Put the authority of Goodman & Gilman's in the palm of your hand! 5 STAR DOODY'S REVIEW! "...the most authoritative and trusted source of pharmacological information, has now spawned a portable pocket drug guide....This manual extracts the essential core drug information from the eleventh edition of the parent book, referring the reader to the online version of the parent book for historical aspects, many chemical and clinical details, and additional figures and references. This makes G & G a very useful book. This will be of use to individuals in training or practice in the fields of pharmacy, medicine, nursing, or allied health disciplines where knowledge of drug actions are important....Each chapter provides the core essential information provided in the parent book in a very readable format. Readers can use this easy to handle and read manual for essential information along with the online version of the parent book as a reference for more in-depth specific information on drugs."--Doody's Review Service The Goodman & Gilman Manual of Pharmacology and Therapeutics offers the renowned content of Goodman & Gilman's Pharmacological Basis of Therapeutics, Eleventh Edition, condensed into an ultra-handy, streamlined reference. More than just a pocket drug guide, this indispensable resource offers: A carry-along source of essential fundamental information, with all the authority of Goodman & Gilman's Pharmacological Basis of Therapeutics, Eleventh Edition The benefits of the world's leading pharmacology text in a convenient, portable format Comprehensive, yet streamlined and clinically relevant coverage of the pharmacological basis of therapeutics High-yield overview of pharmacokinetics, pharmacodynamics, and the foundations of pharmacology Expert insights into the properties, mechanisms, and uses of all the major drug classes Considerations of vital patient-specific issues

- NEW! Restructured table of contents helps you quickly locate information. - NEW! Language from the International Classification of Functioning, Disability, and Health (ICF) model adopted by the American Physical Therapy Association increases your familiarity with terminology. - NEW! New intervention algorithms along with existing algorithms break clinical decision-making into individual steps and sharpens your on-the-spot critical-thinking skills. - NEW! A quick-reference appendix covering abbreviations commonly found in the acute care environment supplies the translation tools you need, while flagging any abbreviations that may be harmful to the patient.